ECM
MLTX icon

ExodusPoint Capital Management’s MoonLake Immunotherapeutics MLTX Stock Holding History

ExodusPoint Capital Management’s Portfolio MLTX Stock Details MLTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-30,000
Closed -$215K – 1859
2025
Q3 		$215K Buy
+30,000
New +$1.56M ﹤0.01% 1373

Other funds holding MLTX

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
WAM
Weiss Asset Management Boston, Massachusetts $5.91B AUM 42.42% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

ExodusPoint Capital Management's MLTX Position: Q1 2026 in Review

ExodusPoint Capital Management reduced its MoonLake Immunotherapeutics (MLTX) stake by 44% in Q1 2026, selling an estimated $1.54M and leaving 120,310 shares worth $2.24M. The position accounts for 0.02% of the portfolio, ranked #746.

ExodusPoint Capital Management first reported a position in MLTX in Q4 2020 and has held it in 11 quarters since. The position peaked at $2.81M in Q4 2025. 147 funds tracked by Wall St. Rank hold MLTX as of Q1 2026.

  • ExodusPoint Capital Management held 120,310 shares of MoonLake Immunotherapeutics worth $2.24M as of Q1 2026.
  • ExodusPoint Capital Management sold 92,686 MoonLake Immunotherapeutics shares in Q1 2026, an estimated $1.54M.
  • MoonLake Immunotherapeutics made up 0.02% of ExodusPoint Capital Management's portfolio in Q1 2026, its #746 holding.
  • ExodusPoint Capital Management first reported a position in MoonLake Immunotherapeutics in Q4 2020 and has held it in 11 quarters since.
  • ExodusPoint Capital Management's MoonLake Immunotherapeutics position peaked at $2.81M in Q4 2025.
  • 147 funds tracked by Wall St. Rank held MoonLake Immunotherapeutics as of Q1 2026.

Based on ExodusPoint Capital Management's 13F filing for Q1 2026, filed 14 May 2026.